Age-related trends in the incidence of metastatic colorectal cancer from 2010 to 2019 in the USA

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022).
   PubMed Web of Science ®Google Scholar
• Zaborowski AM, Abdile A, Adamina M et al. Characteristics of early-onset vs late-onset colorectal cancer: a review. JAMA Surg. 156(9), 865–874 (2021).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA. Increasing incidence of early-onset colorectal cancer. N. Engl. J. Med. 386(16), 1547–1558 (2022).
   PubMed Web of Science ®Google Scholar
• Bailey CE, Hu CY, You YN et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg. 150(1), 17–22 (2015).
   PubMed Web of Science ®Google Scholar
• Wolf AMD, Fontham ETH, Church TR et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 68(4), 250–281 (2018).
   PubMed Web of Science ®Google Scholar
• Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced-stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms or time to diagnosis. Clin. Gastroenterol. Hepatol. 15(5), 728–737; e723 (2017).
   PubMed Web of Science ®Google Scholar
• Mueller M, Schneider MA, Deplazes B, Cabalzar-Wondberg D, Rickenbacher A, Turina M. Colorectal cancer of the young displays distinct features of aggressive tumor biology: a single-center cohort study. World J. Gastrointest. Surg. 13(2), 164–175 (2021).
   PubMed Web of Science ®Google Scholar
• Fu J, Yang J, Tan Y et al. Young patients (≤35 years old) with colorectal cancer have worse outcomes due to more advanced disease: a 30-year retrospective review. Medicine (Baltimore). 93(23), e135 (2014).
   PubMed Web of Science ®Google Scholar
• Van Der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, De Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin. Exp. Metastasis 32(5), 457–465 (2015).
   PubMed Web of Science ®Google Scholar
• Ansa BE, Coughlin SS, Alema-Mensah E, Smith SA. Evaluation of colorectal cancer incidence trends in the United States (2000–2014). J. Clin. Med. 7(2), 22 (2018).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J. Clin. 72(4), 372–401 (2022).
   PubMed Web of Science ®Google Scholar
• O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J. Surg. 28(6), 558–562 (2004).
   PubMed Web of Science ®Google Scholar
• Willauer AN, Liu Y, Pereira AAL et al. Clinical and molecular characterization of early-onset colorectal cancer. Cancer 125(12), 2002–2010 (2019).
   PubMed Web of Science ®Google Scholar
• Saraste D, Järås J, Martling A. Population-based analysis of outcomes with early-age colorectal cancer. Br. J. Surg. 107(3), 301–309 (2020).
   PubMed Web of Science ®Google Scholar
• Montminy EM, Zhou M, Maniscalco L et al. Shifts in the proportion of distant stage early-onset colorectal adenocarcinoma in the United States. Cancer Epidemiol. Biomarkers Prev. 31(2), 334–341 (2022).
   PubMed Web of Science ®Google Scholar
• Benson ABR, Venook AP, Cederquist L et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 15(3), 370–398 (2017).
   PubMed Web of Science ®Google Scholar
• Van CE, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl. 3), iii1–9 (2014).
   PubMedGoogle Scholar
• Yoshino T, Arnold D, Taniguchi H et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 29(1), 44–70 (2018).
   PubMed Web of Science ®Google Scholar
• Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol. Oncol. 13(2), 109–131 (2019).
   PubMed Web of Science ®Google Scholar
• Cavestro GM, Mannucci A, Balaguer F et al. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines. Clin Gastroenterol Hepatol. 21(3), 581–603; e533 (2023).
   PubMed Web of Science ®Google Scholar
• Kneuertz PJ, Chang GJ, Hu CY et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 150(5), 402–409 (2015).
   PubMed Web of Science ®Google Scholar
• Lund CM, Vistisen KK, Dehlendorff C, Rønholt F, Johansen JS, Nielsen DL. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study. Acta. Oncol. 57(11), 1445–1454 (2018).
   PubMed Web of Science ®Google Scholar
• Kolarich A, George TJ Jr, Hughes SJ et al. Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease. Cancer 124(17), 3510–3519 (2018).
   PubMed Web of Science ®Google Scholar
• Lipsyc-Sharf M, Zhang S, Ou FS et al. Survival in young-onset metastatic colorectal cancer: findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. J. Natl Cancer Inst. 114(3), 427–435 (2022).
   PubMedGoogle Scholar
• Cremolini C, Antoniotti C, Rossini D et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21(4), 497–507 (2020).
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25(13), 1670–1676 (2007).
   PubMed Web of Science ®Google Scholar
• Jindal V, Gupta R, Sahu KK, Rahi MS, Stender MJ, Jalyesimi IA. Doublet (FOLFOX or FOLFIRI) versus triplet (FOLFOXIRI) backbone chemotherapy regimen as first-line treatment of metastatic colorectal cancer: a meta-analysis and systematic review. J. Clin. Oncol. 39(Suppl. 15), 3593 (2021).
   Google Scholar
• Marques RP, Duarte GS, Sterrantino C et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 118, 54–62 (2017).
   PubMed Web of Science ®Google Scholar
• Optum®. Optum® Clinformatics® Data Mart (2017). www.optum.com/content/dam/optum/resources/productSheets/Clinformatics_for_Data_Mart.pdf ( Accessed 31 October 2022).
   Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. JAMA 310(20), 2191–2194 (2013).
   PubMed Web of Science ®Google Scholar
• Patel AK, Duh MS, Barghout V et al. Real-world treatment patterns among patients with colorectal cancer treated with trifluridine/tipiracil and regorafenib. Clin. Colorectal Cancer. 17(3), e531–e539 (2018).
   PubMed Web of Science ®Google Scholar
• Fu AZ, Zhao Z, Gao S, Barber B, Liu GG. Comorbid conditions in patients with metastatic colorectal cancer. World J. Oncol. 2(5), 225–231 (2011).
   PubMedGoogle Scholar
• National Cancer Institute. Annual percent change (APC) and confidence interval (2022). https://surveillance.cancer.gov/help/joinpoint/setting-parameters/method-and-parameters-tab/apc-aapc-tau-confidence-intervals/estimate-average-percent-change-apc-and-confidence-interval ( Accessed 31 October 2022).
   Google Scholar
• Optum®. Optum® claims data (2022). www.optum.com/business/solutions/life-sciences/real-world-data/claims-data.html ( Accessed 31 October 2022).
   Google Scholar
• Kiang MV, Humphreys K, Cullen MR, Basu S. Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study. BMJ. 368, l6968 (2020).
   PubMedGoogle Scholar
• Vuik FE, Nieuwenburg SA, Bardou M et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 68(10), 1820–1826 (2019).
   PubMed Web of Science ®Google Scholar
• Siegel RL, Fedewa SA, Anderson WF et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J. Natl Cancer Inst. 109(8), djw322 (2017).
   PubMedGoogle Scholar
• SEER Program. Incidence —SEER research data, 9 registries, Nov 2019 sub (1975–2017). (2019).
   Google Scholar
• Siegel RL, Torre LA, Soerjomataram I et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut 68(12), 2179–2185 (2019).
   PubMed Web of Science ®Google Scholar
• Done JZ, Fang SH. Young-onset colorectal cancer: a review. World J. Gastrointest. Oncol. 13(8), 856–866 (2021).
   PubMed Web of Science ®Google Scholar
• Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990–2010. J. Natl Cancer Inst. 107(10), djv198 (2015).
   PubMedGoogle Scholar
• Murphy CC, Sanoff HK, Stitzenberg KB, Baron JA, Lund JL, Sandler RS. Patterns of sociodemographic and clinicopathologic characteristics of stages II and III colorectal cancer patients by age: examining potential mechanisms of young-onset disease. J. Cancer Epidemiol. 2017, 4024580 (2017).
   PubMedGoogle Scholar